Olema Pharmaceuticals Zukünftiges Wachstum
Future Kriterienprüfungen 0/6
Olema Pharmaceuticals's earnings are forecast to decline at 4.9% per annum while its annual revenue is expected to grow at 72.5% per year. EPS is expected to decline by 4.6% per annum. Return on equity is forecast to be -66.6% in 3 years.
Wichtige Informationen
-4.9%
Wachstumsrate der Gewinne
-4.6%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 27.1% |
| Wachstumsrate der Einnahmen | 72.5% |
| Zukünftige Eigenkapitalrendite | -66.6% |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 01 Nov 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth
Aug 29
Olema Pharmaceuticals: Still Merits A Small Holding
Jun 17Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation
May 11Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path
Mar 28Estimating The Fair Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
Mar 04Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation
Nov 09We're Keeping An Eye On Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate
Jun 11Will Olema Pharmaceuticals (NASDAQ:OLMA) Spend Its Cash Wisely?
Mar 01Olema Oncology grants stock options for 58.3K shares
Oct 05We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate
Sep 13Olema Pharmaceuticals GAAP EPS of -$0.82 misses by $0.18
Aug 09Olema stock soars 12% as FDA grants fast track status to OP-1250 for breast cancer subtype
Jul 21We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Easily Afford To Drive Business Growth
May 29Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth
Feb 08Our Take On Olema Pharmaceuticals
Jan 05We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate
Sep 19We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Afford To Drive Business Growth
Jun 04Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth
Feb 19
Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 8 | -174 | -150 | N/A | 3 |
| 12/31/2025 | N/A | -155 | -137 | -144 | 5 |
| 12/31/2024 | N/A | -130 | -90 | -51 | 5 |
| 6/30/2024 | N/A | -110 | -92 | -92 | N/A |
| 3/31/2024 | N/A | -99 | -87 | -87 | N/A |
| 12/31/2023 | N/A | -97 | -84 | -84 | N/A |
| 9/30/2023 | N/A | -96 | -85 | -85 | N/A |
| 6/30/2023 | N/A | -97 | -81 | -80 | N/A |
| 3/31/2023 | N/A | -110 | -85 | -85 | N/A |
| 12/31/2022 | N/A | -105 | -82 | -82 | N/A |
| 9/30/2022 | N/A | -100 | -82 | -81 | N/A |
| 6/30/2022 | N/A | -95 | -76 | -75 | N/A |
| 3/31/2022 | N/A | -79 | -59 | -58 | N/A |
| 12/31/2021 | N/A | -71 | -52 | -51 | N/A |
| 9/30/2021 | N/A | -60 | -42 | -41 | N/A |
| 6/30/2021 | N/A | -52 | -37 | -37 | N/A |
| 3/31/2021 | N/A | -38 | -29 | -29 | N/A |
| 12/31/2020 | N/A | -24 | -20 | -20 | N/A |
| 9/30/2020 | N/A | -15 | -12 | -12 | N/A |
| 12/31/2019 | N/A | -4 | -3 | -3 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: OLMA is forecast to remain unprofitable over the next 3 years.
Ertrag vs. Markt: OLMA is forecast to remain unprofitable over the next 3 years.
Hohe Wachstumserträge: OLMA is forecast to remain unprofitable over the next 3 years.
Einnahmen vs. Markt: OLMA is forecast to have no revenue next year.
Hohe Wachstumseinnahmen: OLMA is forecast to have no revenue next year.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: OLMA is forecast to be unprofitable in 3 years.